SCHEMBL4773023

SCHEMBL4773023

COc1ccc2c(n1)C(=O)CCCN2C(=O)OC(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
IDO1 P14902 7/20 0.38
KCNH2 Q12809 4/20 0.38
GPR119 Q8TDV5 1/20 0.38
HSD17B10 Q99714 2/20 0.36
CYP2C9 P11712 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
CYP2C19 P33261 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35
SCN9A Q15858 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
CETP P11597 1/20 0.34
CYP3A4 P08684 1/20 0.34
SRD5A1 P18405 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768474 0.84 KDM4E (0.37) KDM4EIDO1KCNH2CYP2C9KMT2A
SCHEMBL4774567 0.79 KDM4E (0.34) KDM4EIDO1KCNH2HSD17B10CYP2C9
SCHEMBL7240958 0.76 HSD17B10 (0.45) KDM4EHSD17B10KMT2AALDH1A1HPGD
SCHEMBL4765266 0.74 HTR2C (0.35) KDM4EIDO1KCNH2HSD17B10CYP2C9
SCHEMBL3535539 0.73 NOTUM (0.48) CYP2C9MEN1CYP2D6MAPTKMT2A
SCHEMBL4768298 0.72 SMN1; SMN2 (0.35) KDM4EIDO1KCNH2MAPTKMT2A
SCHEMBL2475561 0.72 ABHD6 (0.46) KDM4EHSD17B10MEN1MAPTKMT2A
SCHEMBL3537930 0.71 MEN1 (0.42) KDM4EMEN1MAPTKMT2ASCN9A
SCHEMBL3529510 0.71 L3MBTL1 (0.40) KDM4EIDO1KCNH2CYP2C9MEN1
SCHEMBL6033408 0.70 KDM4E (0.43) KDM4EIDO1KCNH2HSD17B10CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732933-B1 COMPOUNDS FOR TREATING DYSLIPIDEMIA LILLY CO ELI (US) 2008-07-23 EP disclosed
US-20070208003-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY 2007-09-06 US disclosed
EP-1732933-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2006-12-20 EP disclosed
WO-2005097805-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208003-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA PCSK9, LIPC, APOB KDM4E 1101/4885IDO1 4375/4885KCNH2 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.